Journal of Neuropsychiatry and Clinical Neurosciences 2008-04-01

Double-blind randomized treatment of poststroke depression using nefiracetam.

Robert G Robinson, Ricardo E Jorge, Kathleen Clarence-Smith

Index: J. Neuropsychiatry Clin. Neurosci. 20(2) , 178-84, (2008)

Full Text: HTML

Abstract

In preliminary trials, nefiracetam, a gamma aminobutyric compound, enhanced blood flow and improved mood following stroke. Within 3 months following stroke with major depression, 159 patients were enrolled in a double-blind trial of nefiracetam or placebo. Repeated measures analysis of covariance failed to show a significant time-by-treatment interaction. Response rates were greater than 70% and remission rates were greater than 40% for nefiracetam and placebo. The top quintile of Hamilton Depression Rating Scale scores showed significant effect after 900 mg of nefiracetam versus 600 mg or placebo. Nefiracetam was not an effective treatment for poststroke depression but produced significant improvement in the most severely depressed patients.

Related Compounds

  • Nefiracetam

Related Articles:

Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam.

2005-09-01

[Arch. Toxicol. 79(9) , 500-7, (2005)]

Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.

2009-05-05

[Neuroscience 160(2) , 484-91, (2009)]

Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats.

2005-06-01

[Epilepsia 46(6) , 811-8, (2005)]

Negative regulation of opioid receptor-G protein-Ca2+ channel pathway by the nootropic nefiracetam.

2004-10-01

[Ann. N. Y. Acad. Sci. 1025 , 389-97, (2004)]

Nefiracetam, a novel cognition-enhancing agent. An introductory overview.

1994-02-01

[Arzneimittelforschung 44(2A) , 193-4, (1994)]

More Articles...